Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2016 - 2025)

Ani Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 12.14% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $5.5 billion, up 24.43%, while the annual FY2025 figure was $1.4 billion, 12.14% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.4 billion at Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2025 and bottomed at $463.8 million in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $874.6 million (2023), against an average of $924.6 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 67.31% in 2021 against a maximum downside of 3.81% in 2021.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then increased by 18.99% to $904.4 million in 2023, then skyrocketed by 42.02% to $1.3 billion in 2024, then rose by 12.14% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Liabilities and Shareholders Equity are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).